Ariane C. Gomes
YOU?
Author Swipe
View article: A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients’ sera
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients’ sera Open
Human cytomegalovirus (HCMV) remains an important cause of mortality in immune-compromised transplant patients and following congenital infection. Such is the burden, an effective vaccine strategy is considered to be of the highest priorit…
View article: The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread Open
View article: Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites
Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites Open
View article: A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19
A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19 Open
View article: IgA binds to the AD‐2 epitope of glycoprotein B and neutralizes human cytomegalovirus
IgA binds to the AD‐2 epitope of glycoprotein B and neutralizes human cytomegalovirus Open
Summary Human cytomegalovirus (HCMV) is a ubiquitous pathogen that is potentially pathogenic in immunosuppressed individuals and pregnant females during primary infection. The HCMV envelope glycoprotein B (gB) facilitates viral entry into …
View article: NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development
NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development Open
Natural killer (NK) cells are innate lymphoid cells that recognize and eliminate virally-infected and cancerous cells. Members of the innate immune system are not usually considered to mediate immune memory, but over the past decade eviden…
View article: Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation Open
View article: Conheça mais sobre a técnica de Harmonização Facial
Conheça mais sobre a técnica de Harmonização Facial Open
View article: Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2
Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2 Open
Inducing T cell responses by therapeutic vaccination requires appropriate activation of antigen presenting cells (APCs). The use of virus-like particles (VLPs) containing Toll-like receptor (TLR) ligands has demonstrated remarkable potenti…
View article: The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation
The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation Open
Human cytomegalovirus (hCMV) is considered to be the highest priority for vaccine development. This view is underscored by the significant morbidity associated with congenital hCMV infection and viraemia in transplant patients. Although a …
View article: Erisipela: causas e tratamento
Erisipela: causas e tratamento Open
View article: Type of RNA Packed in VLPs Impacts IgG Class Switching—Implications for an Influenza Vaccine Design
Type of RNA Packed in VLPs Impacts IgG Class Switching—Implications for an Influenza Vaccine Design Open
Nucleic acid packed within virus-like particles (VLPs) is shown to shape the immune response and to induce stronger B cell responses in different immunisation models. Here, using a VLP displaying the highly conserved extracellular domain o…
View article: Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine Open
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients…
View article: Mutated as well as germ-line epitopes contribute to preclinical efficacy of virus-like particles based cancer vaccines
Mutated as well as germ-line epitopes contribute to preclinical efficacy of virus-like particles based cancer vaccines Open
View article: Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System
Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System Open
Virus-like particles (VLPs) derived from viral nucleocapsids are an important class of nanoparticles. The structure, uniformity, stability, and function of these VLPs have attracted scientists in utilizing them as a unique tool in various …
View article: Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria
Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria Open
Microcrystalline Tyrosine (MCT®) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against mala…
View article: Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles Open
Parkinson's disease (PD) is a progressive and currently incurable neurological disorder characterised by the loss of midbrain dopaminergic neurons and the accumulation of aggregated alpha-synuclein (a-syn). Oligomeric a-syn is proposed to …
View article: Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax Open
Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a we…
View article: Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines
Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines Open
Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe autologous virus-targeting vaccines, the powerful immunogen…
View article: Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination
Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination Open
View article: Harnessing Nanoparticles for Immunomodulation and Vaccines
Harnessing Nanoparticles for Immunomodulation and Vaccines Open
The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel…